Just a few years ago, it would have been unthinkable to offer testosterone therapy (TTh) to men with a history of prostate cancer. Yet several changes have occurred to make TTh a reasonable treatment option in men who are symptomatic from testosterone deficiency.
The relationship between T and prostate cancer has been a primary interest of mine, and it has been fascinating to watch the transformation in thought and practice over the last 20 years. In this article, I will present our current understanding of this topic and its impact on clinical practice.
From evidence to practice: Dr. Makarov discusses implementation science in urology
July 25th 2024“What our major contribution is, I think as urologists doing implementation science, is determining the important questions, which we are particularly well-suited to do because we're taking care of the patients,” says Danil V. Makarov, MD, MHS.